| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 30 | — | 17.8x | Bottom tier | |
Growth | 85 | 28.0% | 7.1% | Top tier | |
Quality | 39 | -7.6% | 4.5% | Bottom tier | |
Safety | 36 | — | 2.6x | Bottom tier | |
Capital Return | 19 | — | 2.12% | Bottom tier | |
Momentum | 44 | -26.4% | 2.9% | Around median | |
Sentiment | 41 | 8 | 3 | Around median |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Hims & Hers Health operates a consumer telehealth platform that connects subscribers with healthcare providers, treatments, pharmacies, and follow-up services through an integrated digital experience. The company generates revenue by providing care and treatments in specialties including weight loss, sexual health, hair loss, and low testosterone, while expanding laboratory testing and hormonal care services. In Q2 FY2026, it added more than 300 thousand subscribers, bringing its global subscriber base to nearly 3 million, while five U.S. specialties reached annual revenue run rates exceeding $100 million each.
Revenue in Q2 FY2026 was approximately $753.2 million, up about 38% year over year, while gross profit reached $480.8 million at a gross margin of 64%. The company recorded a GAAP net loss of $86.3 million and a loss per share of $0.37, compared with net income of $128.4 million in FY2025. By geographic mix, U.S. operations generated $622 million, representing nearly 83% of quarterly revenue, while international revenue totaled $131 million, including approximately $40 million from Eucalyptus.
Automated analysis for informational purposes only — not investment advice.
The average analyst price target is $30.2, within a wide range of $12.5 to $42, with a Neutral consensus; the average is approximately 54% below the 52-week high of $65.299 and approximately 120% above the low of $13.74. There is no positive earnings multiple because of the trailing loss per share in 2026, and the wide valuation range reflects a balance between revenue growth and raised guidance versus the Q2 FY2026 losses, margin contraction, the FTC case, and Deutsche Bank's price-target reduction to $26.
Figures in the text are as of 2026-08-30; the live price is shown at the top of the page.
Revenue increased to $753.2 million, up approximately 38% year over year, after adding more than 300 thousand subscribers and reaching nearly 3 million subscribers globally. The expansion of the branded weight-loss product portfolio in March 2026 helped accelerate U.S. revenue to 16% growth and a total of $622 million. International revenue also reached $131 million, including approximately $40 million contributed by Eucalyptus following the completion of the acquisition in June 2026.
The company recorded a net loss of $86.3 million and a loss per share of $0.37 in Q2 FY2026. In contrast, adjusted EBITDA was $60 million at an 8% margin after excluding approximately $81 million in acquisition costs, restructuring costs, and legal provisions. Management expects adjusted EBITDA of $275 million to $325 million for FY2026, but the company recorded negative free cash flow of $68 million during the quarter.
In early July 2026, the company began rolling out an AI-powered experience for Hers weight-loss customers that connects support, the care team, the provider, and the pharmacy within a single platform. Participants sent three times the usual number of messages, and the system answered 80% of their questions. The experience reduced non-clinical tasks for support teams by approximately 50%, while keeping clinical decisions under the supervision of healthcare providers and targeting a return on investment within 12 to 18 months.
Hims & Hers completed the acquisition of Eucalyptus in June 2026, and management described it as the largest acquisition in the company's history. Eucalyptus contributed approximately $40 million to Q2 FY2026 revenue, while total international revenue reached $131 million. The company is targeting at least $600 million in international revenue during FY2026, but these operations are expected to operate at or near breakeven on an adjusted EBITDA basis as investment in expansion continues.
Three quarters after its launch, testosterone became the fastest-growing specialty outside weight loss, and the company expects it to become the sixth U.S. specialty to exceed an annual revenue run rate of $100 million. Hims & Hers plans to expand the portfolio to injectable and oral testosterone and is also targeting the introduction of sermorelin, glutathione, and NAD+ before the end of 2026. As for the six peptides discussed by PCAC, the company will not launch them before the FDA's final decision is complete, despite having begun stability and validation testing for the active ingredients at the Menlo Park facility.
The FTC filed a complaint on July 29, 2026, concerning the sharing of sensitive health data and billing practices, followed by a class-action lawsuit filed by Lowey Dannenberg on behalf of consumers. Financially, adjusted gross margin declined by approximately six points quarter over quarter to 64% in Q2 FY2026, and management expects mix pressure to continue during the second half. The company also recorded negative operating cash flow of $36 million and negative free cash flow of $68 million in the quarter, despite expecting to resume generating free cash flow in the second half.
